MVA85A
MVA85A (modified vaccinia Ankara 85A) is a new-generation vaccine against tuberculosis developed by researchers at Oxford University. This vaccine produces higher levels of long-lasting cellular immunity when used together with the old TB vaccine called BCG.[1] Phase I clinical trials have been completed[2] and phase II clinical trials are currently underway in South Africa.[3]
External links
References
- ^ McShane H, Pathan AA, Sander CR, et al. (2004). "Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG primed and naturally acquired anti-microbial immunity in humans". Nat Med 10 (11): 1240–44. doi:10.1038/nm1128. PMID 15502839.
- ^ Hawkridge T, Scriba TJ, Gelderbloem, et al. (2008). "Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa". J Infect Dis 198 (4): 544–52. doi:10.1086/590185. PMC 2822902. PMID 18582195. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2822902.
- ^ Ibanga H, Brookes R, Hill P, Owiafe P, Fletcher H, Lienhardt C, Hill A, Adegbola R, McShane H (2006). "Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design". Lancet Infect Dis 6 (8): 522–8. doi:10.1016/S1473-3099(06)70552-7. PMID 16870530.
|
|
|
| Development |
|
|
| Administration |
|
|
| Vaccines |
|
Bacterial
|
|
|
|
Viral
|
|
|
|
Protozoan
|
|
|
|
|
|
|
|
Other
|
|
|
|
| Controversy |
|
|
| See also |
|
|
|
|
|
gr+f/gr+a(t)/gr-p(c)/gr-o
|
|
|
|
|
|
cutn/syst (hppv/hiva, infl/zost/zoon)/epon
|
drugJ(dnaa, rnaa, rtva, vacc)
|
|
|
|